depression

News

AbbVie adds to neuroscience pipeline with $1bn Syndesi buy

Four years after spinning out from Belgium's UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought by AbbVie for $130 million upfront.

News

AbbVie files Vraylar as add-on therapy for depression in US

AbbVie has filed with the FDA to extend the uses of its bipolar disorder therapy Vraylar to include adjunctive therapy for major depressive disorder, part of a plan to build sales of the dr

News

Sage, Biogen's zuranolone looks approvable, but will it sell...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response.

News

Blue Note leukaemia DTx gets FDA breakthrough tag

A prescription digital therapeutic (DTx) for leukaemia patients developed by Blue Note Therapeutics has been awarded breakthrough device status by the FDA.

News

Compass points to positive psilocybin trial, but shares fall

Compass Pathways has reported that its drug for treatment-resistant depression (TRD) based on magic mushroom ingredient psilocybin was effective in a phase 2b trial, although shares in the

News

Biogen, Sage prep 2022 filing for depression drug zuranolone

The renaissance of Biogen and Sage Therapeutics antidepressant zuranolone continues, with the companies indicating they now plan to start a rolling submission for the drug early next year.<

AbbVie adds to neuroscience pipeline with $1bn Syndesi buy

AbbVie files Vraylar as add-on therapy for depression in US

Sage, Biogen's zuranolone looks approvable, but will it sell...

Blue Note leukaemia DTx gets FDA breakthrough tag

Compass points to positive psilocybin trial, but shares fall

Biogen, Sage prep 2022 filing for depression drug zuranolone

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

depression

Editor's Picks